GleamWall
中文EN

ADVB Advanced Biomed Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1941029 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY279.7%
TTM EPS YoY244.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE85.0%
ROA63.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets12.5%
Debt / equity0.00x
Current ratio8.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.25x
Accruals ratio79.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue$127,637—
R&D expense—$909,771
SG&A expense$4.63M$1.09M
Operating income-$6.23M-$1.09M
Pretax income-$6.26M-$1.09M
Income tax-$1,205—
Net income$6.68M-$3.26M
EBITDA—-$742,640
EPS (basic)5.33-3.18
EPS (diluted)5.33-3.18
Weighted avg. shares (diluted)1.25M1.03M
Balance sheet
Cash & equivalents$385,535$31,139
Current assets$13.75M$22.38M
PP&E, net—$125,184
Total assets$13.75M$22.86M
Current liabilities$1.47M$19.24M
Total liabilities$1.47M$19.38M
Shareholders' equity$12.28M$3.48M
Shares outstanding1.65M1.08M
Cash flow statement
Operating cash flow-$1.95M-$5.83M
Capital expenditure—$31,650
Free cash flow—-$5.86M
Investing cash flow-$2.51M-$31,650
Financing cash flow$1.97M$5.93M
Depreciation & amortization—$343,830
Stock-based compensation$1.73M—

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.